BOLD News and Press, Audentes Therapeutics Inc. From 12/04/19

Congratulations to Sundar Pichai, this is what you need to do with Alphabet Can you please just dump the Alphabet (GOOG) (GOOGL) name and go back to Google? No one calls you Alphabet, so it just confuses everyone. Also "Other bets" are like 0.07% of revenue, so do you really need a holdi...

Shares of Regenxbio ( RGNX ) have risen by 190% since I initially uncovered and recommended a position in this gene therapy pioneer in 2016. The stock has appreciated by just 52% since my February 2018 update piece . With the recently announced acquisition of collaboration partner Auden...

December 4, 2019 Palm Beach, FL –December 4, 2019 – So it is not surprising that there is a lot of money and research resources being devoted to find new therapies for Acute Myeloid Leukemia (AML), many of which are in the targeted drugs arena. AML is the second most com...

Tuesday was a bad day on Wall Street, as major benchmarks fell sharply on news from the White House regarding trade. President Trump said that it might be better for the U.S. not to expect a trade deal with China until after the 2020 presidential election, throwing cold water on recent hopes tha...

Shares of  Audentes Therapeutics (NASDAQ: BOLD)  are skyrocketing today, up by 105% as of 2:47 p.m. EST, after the clinical-stage  gene therapy specialist announced it has agreed to be acquired. Astellas Pharma, a pharmaceutical company based in Japan, has agreed to purch...

After big biopharma Astellas   (OTC: ALPMY) (OTC: ALPMF) agreed to acquire clinical-stage gene therapy company Audentes Therapeutics (NASDAQ: BOLD) for $3 billion in cash, uniQure 's (NASDAQ: QURE) shares have jumped 13% at 12:15 pm EDT on Tuesday. Although Audentes and uni...

Gainers:  Audentes Therapeutics (NASDAQ: BOLD ) +105% . More news on: Audentes Therapeutics, Inc., ViewRay, Inc., Outlook Therapeutics, Inc., Stocks on the move, Read more ...

Audentes Therapeutics (NASDAQ: BOLD )  +105%  as Astellas Pharma to buy Audentes Therapeutics for $60/share. More news on: Audentes Therapeutics, Inc., ViewRay, Inc., uniQure N.V., Stocks on the move, Read more ...

NEW YORK, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Audentes Therapeutics, Inc. (NASDAQ: BOLD) to Astellas Pharma Inc. (“Astellas”) for $60.00 per share is fair to Audentes shareholders. On behal...

Audentes Therapeutics (NASDAQ: BOLD ) agrees to be acquired by Astellas Pharma ( OTCPK:ALPMF ) for US$60/share in cash, representing a total equity value of ~US$3B; shares are halted. More news on: Audentes Therapeutics, Inc., Astellas Pharma Inc., Astellas Pharma Inc., Healthcare stocks...